Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder | Zendy

Ann Childress | Zendy; Shailly Mehrotra | Zendy; Jogarao Gobburu | Zendy; Angus M. McLean | Zendy; Norberto J. DeSousa | Zendy; Bev Incledon | Zendy

Open Access

Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder

Author(s) -

Ann Childress,

Shailly Mehrotra,

Jogarao Gobburu,

Angus M. McLean,

Norberto J. DeSousa,

Bev Incledon

Publication year - 2017

Publication title -

journal of child and adolescent psychopharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.935

H-Index - 84

eISSN - 1557-8992

pISSN - 1044-5463

DOI - 10.1089/cap.2017.0044

Subject(s) - pharmacokinetics , tolerability , cmax , methylphenidate , morning , evening , attention deficit hyperactivity disorder , area under the curve , medicine , pharmacology , adverse effect , psychiatry , physics , astronomy

Current extended-release (ER) formulations of psychostimulants used for treatment of attention-deficit/hyperactivity disorder (ADHD) provide an extended duration of ADHD symptom control; however, the onset of efficacy can be protracted and variable, leaving the early morning untreated. The primary objective was to characterize the single-dose pharmacokinetics and tolerability of HLD200, an evening-dosed, delayed-release (DR) and ER formulation of methylphenidate (MPH), in healthy adults and in adolescents and children with ADHD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research